TBPMF News and Press, Tetra Bio-Pharma Inc From 12/06/22

Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir Canada NewsWire The combination of ARDS-003 and Favipiravir presents viable treatments against viral infections. Results from the PIONEER clinical trial ...

Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 Canada NewsWire Tetra strengthens its intellectual property position with PCT and provisional patent applications for its innovative therapeutic, ARDS-003. MONTREAL ...

Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission Canada NewsWire MONTREAL , Nov. 18, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug disc...

Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean Canada NewsWire OTTAWA, ON , Oct. 27, 2022 /CNW/ - Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in c...

Tetra and Prepaire Jointly Apply to BARDA for Funding Canada NewsWire Companies jointly submitted a $750,000 USD application to BARDA to use Prepaire™ Shield discovery platform to assess repurposed drugs combined with onternabez as Chemical...

Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean Canada NewsWire OTTAWA, ON , Sept. 8, 2022 /CNW/ - Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM...

Tetra Bio-Pharma ( OTCQB:TBPMF ) and Cellvera Global Holdings are collaborating to develop oral drug ARDS-003 as a combination product, with Qifenda 400MG (Favipiravir), to treat patients with COVID-19. Tetra said Cellvera owns the rights to the brand originator Fa...

Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients Canada NewsWire Tetra and Cellvera to jointly develop an orally administered treatment, ARDS-003, in combination with the proven broad-spectrum antiviral, Qifenda 4...

Tetra Bio-Pharma ( OTCQB:TBPMF ) said it signed a subscription agreement with Global Corporate Finance Opportunities 16, an investment vehicle advised by Alpha Blue Ocean (ABO). Under the agreement, Tetra has agreed to issue to the investor senior unsecured convertible deb...

Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean Canada NewsWire OTTAWA, ON , Aug. 11, 2022 /CNW/ - Tetra Bio-Pharma Inc. (" Tetra " or the " Company ") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoi...